drugset
Drugs / BI 764198
last change Apr 2026 re-read 3 minutes ago

BI 764198

targets TRPC6 via inhibition

Developed for
chronic kidney disease · COVID-19 · focal segmental glomerulosclerosis · proteinuria
Investigated by
Boehringer Ingelheim

Trials 13

today NCT07355296 · Ph 2 NCT07220083 · Ph 3 NCT07308652 · Ph 1 NCT07368569 · Ph 1 NCT06955754 · Ph 1 NCT05863130 · Ph 1 NCT05213624 · Ph 2 NCT04665700 · Ph 1 NCT04656288 · Ph 1 NCT04604184 · Ph 2 NCT04176536 · Ph 1 NCT04102462 · Ph 1 NCT03854552 · Ph 1
20192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 19 trials
Phase 1 NCT07308652 Feb → Mar 2026 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT07368569 Feb → Mar 2026 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT06955754 May → Jun 2025 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT05863130 May → Nov 2023 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT04665700 Feb → Oct 2021 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT04656288 Jan → Mar 2021 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT04176536 Dec 2019 → Nov 2020 chronic kidney disease Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT04102462 Oct 2019 → Oct 2020 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT03854552 Mar → Aug 2019 — Boehringer Ingelheim Completed No outcome recorded
Phase 23 trials · 1 missed
Phase 2 NCT07355296 Mar 2026 → Jan 2028 expected proteinuria Boehringer Ingelheim Recruiting No outcome recorded
Phase 2 NCT05213624 May 2022 → Jan 2025 chronic kidney disease Boehringer Ingelheim Completed Mixed
Phase 2 NCT04604184 Nov 2020 → Mar 2021 COVID-19 Boehringer Ingelheim Terminated Missed primary
Phase 31 trial
Phase 3 NCT07220083 Feb 2026 → Dec 2028 expected focal segmental glomerulosclerosis Boehringer Ingelheim Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as BI 764198 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04665700 ↗
12

NCT04176536 ↗

NCT07220083 ↗

NCT04102462 ↗

NCT03854552 ↗

NCT07368569 ↗

NCT05863130 ↗

NCT06955754 ↗

NCT07355296 ↗

NCT05213624 ↗

NCT04604184 ↗

Show 2 more sources
Action Inhibit “transient receptor potential channel 6 inhibitor” PMID 40455255 ↗ Jun 2025
Route Oral “following oral administration of single rising doses” NCT03854552 ↗
Target TRPC6 “BI 764198, a transient receptor potential channel 6 inhibitor” PMID 40455255 ↗ Jun 2025